# Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)

> **NCT01597505** · PHASE3 · COMPLETED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 606 (actual)

## Conditions studied

- Clostridium Difficile Infection

## Interventions

- **DRUG:** Surotomycin
- **DRUG:** Vancomycin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01597505
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-16
- **Primary completion:** 2015-03-20
- **Final completion:** 2015-03-20
- **Target enrollment:** 606 (ACTUAL)
- **Last updated:** 2019-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01597505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01597505, "Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01597505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*